Hiprabovis Somni/Lkt
Active substance
ATC code
Species
Cattle from 2 months of age.
Indications
To reduce the clinical signs and lung lesions caused by Mannheimia haemolytica serotype A1 and Histophilus somni in calves from 2 months of age.
Onset of immunity:
3 weeks.
Duration of protection:
Not demonstrated.
Dose to be administered and administration route
For subcutaneous use.
Cattle: 2 ml / animal.
Recommended vaccination scheme: Administer one dose (2 ml) per calf, at 2 months of age. This 2 ml dose should be repeated after 21 days. Vaccinate calves by subcutaneous injection in the prescapular area. It is preferable to administer the second dose on alternate sides.
The vaccine should be allowed to warm to a temperature between 15 - 20°C before administration. Shake before use. Avoid the introduction of contamination during use. Use only sterile needles and syringes for administration.
Vaccination is recommended to be used before stress periods (shipping, allotments…). The vaccination scheme should be completed 3 weeks before such periods. Protection has not been demonstrated if vaccination scheme is completed earlier than 3 weeks before stress periods.
Adverse reactions
Very common: A transient rise in temperature (up to 2 ºC) after each vaccination can occur but this resolves after 4 days. Vaccinated animals might show a local swelling at the injection site of 1 to 7 cm after administration of the vaccine. This swelling will have disappeared or be clearly reduced in size by 14 days post vaccination however in some cases swelling may persist for up to 4 weeks after the second administration.
Common: Mild apathy, anorexia and/or depression may be observed after each injection but these resolve within 4 days.
Very rare: Anaphylactic-type reactions may occur in some sensitive animals. In such cases, appropriate symptomatic treatment such as antihistamines or cortisone or in more severe cases adrenaline should be given.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment).
- common (more than 1 but less than 10 animals in 100 animals).
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
